The report forecasts the global CLL therapeutics market to grow at a CAGR of 19.16% during the period 2016-2020.
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
Commenting on the report, an analyst from the research team said: A trend that is expected to boost market growth is a rise in the development of combination therapies. Combination therapies for the treatment of CLL were available only in the form of chemotherapy combination drugs. The approved combinations are chlorambucil in combination with prednisone, and a combination of cyclophosphamide with vincristine and prednisone. However, a growing trend of developing combination therapies to treat CLL has been observed. For instance, TG Therapeutics develops TG-1101 in combination with ibrutinib to treat CLL and MCL. Similarly, the company also develops TG-1101 in combination with TGR-1202 to treat CLL and NHL.
According to the report, a key growth driver is the special regulatory designations offered to certain drugs. Diseases that affect a small percentage of the population, such as CLL, are treated by a few marketed drugs. A small number of patients implies that there is a small market for these0 drugs, so it may not be profitable for companies to develop these drugs as recovering the R&D expenses would be difficult. To compensate for this limitation and encourage the development of such drugs, regions such as the US and the EU award an Orphan Drug Designation or Breakthrough Therapy Designation to certain drugs.